Clinical trials: no Conditions
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Lung Cancer, Non-Small Cell
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT00073008
- Testing
- GW572016 (lapatinib)
- Where
- 31 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Nasal Polyps
A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)
This study will evaluate the effectiveness and safety of MFNS in improving nasal congestion/obstruction and in reducing bilateral nasal polyps.
- Trial name
- NCT01386125
- Testing
- Mometasone Furoate Nasal Spray (MFNS)
- Volunteers
- 748 people
- Sponsor
- Organon and Co
Metastatic Cancer
Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment
This study will be conducted in patients with metastatic cancer and either moderate, severe, or no hepatic impairment who have failed other antineoplastic therapies or for whom there is no standard therapy.
- Trial name
- Hepatic (NCT01632436)
- Testing
- Pixantrone
- Where
- United States
- Sponsor
- CTI BioPharma
Cystic Fibrosis
Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis
Cystic Fibrosis is defined as a genetic disorder affecting approximately 100,000 individuals worldwide. CF is caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene.
- Trial name
- NCT01958944
- Testing
- Nitric oxide
- Where
- 2 sites in Israel
- Volunteers
- 9 people
- Sponsor
- Beyond Air Inc.
Head and Neck Neoplasms
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell cancer.
- Trial name
- NCT00768664
- Testing
- PF-00299804
- Where
- 10 sites in Canada
- Volunteers
- 69 people
- Sponsor
- Pfizer
Primary Neoplasm, Secondary Neoplasm
Nutritional Supplementation in Patients With no Signs of Malnutrition
The aim of the study was to assess the effect of nutritional supplementation on nutritional status and postoperational complications in cancer patients with no clinical signs of malnutrition
- Conditions
- Primary Neoplasm, Secondary Neoplasm, Abdominal Neoplasm
- Trial name
- NCT01894828
- Testing
- Nutritional supplements
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- MedSource Polska
Type 2 Diabetes
Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, Two way crossover, Oral Bioequivalence Study of test product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg film coated tablets of Humanis…
- Trial name
- NCT07266779
- Testing
- Ertugliflozin/Metformin film coated tablets, Segluromet film coated tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
No Condition
A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males
Part A The primary objective of this study is to determine the single dose pharmacokinetics (PK) of ketoprofen lysine salt combined with gabapentin (KLS-GABA [80 mg-34 mg]) compared to KLS alone (80 mg) in healthy male subjects.
- Trial name
- NCT04802967
- Testing
- Ketoprofen Lysine Salt combined with Gabapentin, Ketoprofen Lysine Salt, Gabapentin
- Where
- United Kingdom
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Dompé Farmaceutici S.p.A
Breast Neoplasms, Neoplasm Metastasis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth…
- Trial name
- NCT07174336
- Testing
- LY4064809, Ribociclib, Palbociclib
- Where
- 363 sites in United States, Argentina and 17 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
no Condition
Ascending Dose Tolerability Trial and PK Assessment in Healthy Volunteers After Single & Multiple Oral Intake of DF2755A
Primary objective: •To evaluate the tolerability and safety of ascending single doses of DF2755A in healthy adult male and female volunteers.
- Trial name
- NCT04803396
- Testing
- DF2755A
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Dompé Farmaceutici S.p.A
Hepatitis B, Chronic
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been…
- Trial name
- NCT01641926
- Testing
- PEG-Intron™, PEGASYS™
- Volunteers
- 402 people
- Sponsor
- Merck Sharp & Dohme LLC
Infection, Bacterial Infection
Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection
The purpose of this study is to test whether a U.S. Food and Drug Administration (FDA) approved laboratory test (PCT Kryptor) can help doctors make better decisions on the need for antibiotic therapy in ICU patients with…
- Conditions
- Infection, Bacterial Infection, Sepsis
- Trial name
- NCT00407147
- Testing
- Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brahms AG
Intermittent Claudication
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
Peripheral arterial disease (PAD) is almost invariably associated with a generalized atherosclerotic involvement of the arterial tree and endothelial dysfunction.
- Trial name
- NCT01256775
- Testing
- NCX-4016
- Where
- Italy
- Volunteers
- 442 people
- Sponsor
- NicOx Research Institute S.r.l.
Critical Limb Ischemia
PROMISE International
The objective of this post-market study is to evaluate the safety and effectiveness of the LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization in subjects with critical limb ischemia.
- Trial name
- NCT03321552
- Testing
- Percutaneous deep vein arterialization, LimFlow System
- Where
- 12 sites in Austria, Germany and 3 more
- Volunteers
- 34 people
- Sponsor
- LimFlow SA
Non-24-Hour Sleep-Wake Disorder
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception
The purpose of this study is to evaluate the safety of tasimelteon in male and female patients who suffer from Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01429116
- Testing
- tasimelteon
- Where
- 22 sites in United States
- Volunteers
- 200 people
- Sponsor
- Vanda Pharmaceuticals
Chronic Pain, Osteoarthritis
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic
The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in participants suffering from severe chronic pain due to osteoarthritis of the knee who are…
- Trial name
- NCT00983073
- Testing
- Tapentadol
- Where
- 24 sites in France, Germany and 3 more
- Volunteers
- 224 people
- Sponsor
- Grünenthal GmbH
Arrhythmias, Cardiac
CanGaroo® Registry Study
A Multi-Center Registry Evaluating Participants Who Receive CanGaroo Envelope or No Envelope During their CIED Implantation
- Trial name
- NCT04846127
- Testing
- CanGaroo Envelope
- Where
- 23 sites in United States
- Volunteers
- 500 people
- Sponsor
- Elutia Inc.
Urolithiasis, Stones, Kidney
Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology
The goal of this clinical trial is to compare Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System and standard ureteroscopy (URS) with laser lithotripsy for the treatment of urolithiasis.
- Conditions
- Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
- Trial name
- TRUST (NCT07101809)
- Testing
- Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System, Standard Ureteroscopy (URS)
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- Calyxo, Inc.
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals